Skip to main content
SpringerLink
Log in

Amylin, Amyloid and Age-Related Disease

  • Review Article
  • Physiological Aspects of Aging
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Amylin, a 37-amino acid peptide, is cosecreted with insulin from the β-cells of the pancreatic islets in normal response to physiological stimuli. It is the major protein of islet amyloid, which is usually present in the pancreases of people with non-insulin-dependent (type II) diabetes mellitus. Amylin elicits potent effects on carbohydrate metabolism in rodent tissues, causing insulin resistance in skeletal muscle and liver.

A close structural relationship exists between amylin and the 2 calcitonin gene-related peptides, which are widely distributed neuropeptides and potent vasodilators. These exert biological effects similar to those of amylin on the organs primarily responsible for the regulation of carbohydrate metabolism. All 3 peptides are thought to cause their biological actions by binding to similar cell surface receptors.

This article reviews the field of amylin and its role in the physiological regulation of carbohydrate metabolism, and in disease mechanisms associated with insulin resistance in diabetes mellitus, impaired glucose tolerance and essential hypertension. Potential therapeutic applications are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cooper GJS, Willis AC, Clark A, et al. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 1987; 84: 8628–32

    Article  PubMed  CAS  Google Scholar 

  2. Westermark P, Wernstedt C, Wilander E, et al. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 1987; 84: 3881–5

    Article  PubMed  CAS  Google Scholar 

  3. Cooper GJS, Day AJ, Willis AC, et al. Amylin and the amylin gene: structure, function and relationship to islet amyloid and to diabetes mellitus. Biochim Biophys Acta 1989; 1014: 247–58

    Article  PubMed  CAS  Google Scholar 

  4. Johnson KH, O’Brien TD, Betsholtz C, et al. Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N Engl J Med 1989; 321: 513–8

    Article  PubMed  CAS  Google Scholar 

  5. Kanatsuka A, Makino H, Ohsawa H, et al. Secretion of islet amyloid polypeptide in response to glucose. FEBS Lett 1989; 259: 199–201

    Article  PubMed  CAS  Google Scholar 

  6. Ogawa A, Harris V, McCorkle SK, et al. Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J Clin Invest 1990; 85: 973–6

    Article  PubMed  CAS  Google Scholar 

  7. Kahn SE, D’Alessio DA, Schwartz MW, et al. Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 1990; 39: 634–8

    Article  PubMed  CAS  Google Scholar 

  8. Moore CX, Cooper GJS. Co-secretion of amylin and insulin from cultured islet β-cells: modulation by nutrient secreta-gogues, islet hormones and hypoglycemic agents. Biochem Biophys Res Commun 1991; 179: 1–9

    Article  PubMed  CAS  Google Scholar 

  9. Westermark P, Wilander E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 1978; 15: 417–21

    Article  PubMed  CAS  Google Scholar 

  10. Cooper GJS, Leighton B, Willis AC, et al. The amylin superfamily: a novel grouping of biologically active polypeptides related to the insulin A-chain. Prog Growth Factor Res 1989; 1: 99–105

    Article  PubMed  CAS  Google Scholar 

  11. Ishida-Yamamoto A, Tohyama M. Calcitonin gene-related peptide in the nervous tissue. Prog Neurobiol 1989; 33: 335–86

    Article  PubMed  CAS  Google Scholar 

  12. Brain SD, Williams TJ, Tippins JR, et al. Calcitonin gene-related peptide is a potent vasodilator. Nature 1985; 313: 54–6

    Article  PubMed  CAS  Google Scholar 

  13. Girgis SI, MacDonald DWR, Stevenson JC, et al. Calcitonin gene-related peptide: potent vasodilator and major product of the calcitonin gene. Lancet 1985; II: 14–6

    Article  Google Scholar 

  14. O’Halloran DJ, Bloom SR. Calcitonin gene related peptide: a major neuropeptide and the most powerful vasodilator known [editorial]. BMJ 1991; 302: 739–40

    Article  PubMed  Google Scholar 

  15. Cooper GJS. Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. Endocr Rev 1994; 15: 163–201

    PubMed  CAS  Google Scholar 

  16. Cooper GJS, Leighton B, Dimitriadis GD, et al. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci USA 1988; 85: 7763–6

    Article  PubMed  CAS  Google Scholar 

  17. Leighton B, Cooper GJS. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 1988; 335: 632–5

    Article  PubMed  CAS  Google Scholar 

  18. Young DA, Deems RO, Deacon RW, et al. Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro. Am J Physiol 1990; 259: E457–61

    PubMed  CAS  Google Scholar 

  19. Molina JM, Cooper GJS, Leighton B, et al. Induction of insulin resistance in vivo by amylin and calcitonin gene-related peptide. Diabetes 1990; 39: 260–5

    Article  PubMed  CAS  Google Scholar 

  20. Koopmans SJ, van Mansfeld ADM, Jansz HS, et al. Amylin-induced in vivo insulin resistance in conscious rats: the liver is more sensitive to amylin than peripheral tissues. Diabetologia 1991; 34: 218–24

    Article  PubMed  CAS  Google Scholar 

  21. Frontoni S, Choi SB, Banduch D, et al. In vivo insulin resistance induced by amylin primarily through inhibition of insulin-stimulated glycogen synthesis in skeletal muscle. Diabetes 1991; 40: 568–73

    Article  PubMed  CAS  Google Scholar 

  22. Leighton B, Foot E. The effects of amylin on carbohydrate metabolism in skeletal muscle in vitro and in vivo. Biochem J 1990; 269: 19–23

    PubMed  CAS  Google Scholar 

  23. Young AA, Mott DM, Stone K, et al. Amylin activates glycogen Phosphorylase in the isolated soleus muscle of the rat. FEBS Lett 1991; 281: 149–51

    Article  PubMed  CAS  Google Scholar 

  24. Deems RO, Deacon RW, Young DA. Amylin activates glycogen Phosphorylase and inactivates glycogen synthase via a cAMP-independent mechanism. Biochem Biophys Res Commun 1991; 174: 716–20

    Article  PubMed  CAS  Google Scholar 

  25. Gómez-Foix AM, Rodriguez-Gil JE, Guinovart JJ. Anti-insulin effects of amylin and calcitonin gene-related peptide on hepatic glycogen metabolism. Biochem J 1991; 276: 607–10

    PubMed  Google Scholar 

  26. Wang M-W, Young AA, Rink TJ, et al. 8–37h-CGRP antagonizes actions of amylin on carbohydrate metabolism in vitro and in vivo. FEBS Lett 1991; 291: 195–8

    Article  PubMed  CAS  Google Scholar 

  27. Sowa R, Sanke T, Hirayama J, et al. Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs. Diabetologia 1990; 33: 118–20

    Article  PubMed  CAS  Google Scholar 

  28. Young AA, Gedulin B, Wolfe-Lopez D, et al. Interaction of amylin and insulin in the isolated soleus muscle of the rat: concentration-response relations for co-secreted non-competitive antagonists. Am J Physiol 1992; 263: E274–81

    PubMed  CAS  Google Scholar 

  29. Leighton B, Cooper GJS. The role of amylin in the insulin resistance of non-insulin-dependent diabetes mellitus. Trends Biochem Sci 1990; 15: 295–9

    Article  PubMed  CAS  Google Scholar 

  30. Bremerton-Watt D, Ghatei MA, Bloom SR, et al. Altered islet amyloid polypeptide (amylin) gene expression in rat models of diabetes. Diabetologia 1989; 32: 881–3

    Article  Google Scholar 

  31. Gill AM, Yen TT. Effects of ciglitazone on endogenous plasma islet amyloid polypeptide and insulin sensitivity in obese-diabetic viable yellow mice. Life Sci 1991; 48: 703–10

    Article  PubMed  CAS  Google Scholar 

  32. Jamal H, Bretherton-Watt D, Suda K, et al. Islet amyloid polypeptide-like immunoreactivity (amylin) in rats treated with dexamethasone and streptozotocin. J Endocrinol 1990; 126: 425–9

    Article  PubMed  CAS  Google Scholar 

  33. Huang H-JS, Young AA, Koda JE, et al. Hyperamylinemia, hyperinsulinemia, and insulin resistance in genetically obese LA/N-cp rats. Hypertension 1992; 19 Suppl. I: I101–9

    Article  PubMed  CAS  Google Scholar 

  34. Gedulin B, Cooper GJS, Young AA. Amylin secretion from the perfused pancreas: dissociation from insulin and abnormal elevation in insulin-resistant diabetic rats. Biochem Biophys Res Commun 1991; 180: 782–9

    Article  PubMed  CAS  Google Scholar 

  35. Cooper GJS. Amylin and insulin co-replacement therapy for insulin-dependent (type 1) diabetes mellitus. Med Hypoth 1991; 36: 284–8

    Article  CAS  Google Scholar 

  36. Lukinius A, Wilander E, Westermark GT, et al. Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 1989; 32: 240–4

    Article  PubMed  CAS  Google Scholar 

  37. Clark A, Edwards CA, Ostle LR, et al. Localization of islet amyloid peptide in lipofuscin bodies and secretory granules of human B-cells and in islets of type-2 diabetic subjects. Cell Tissue Res 1989; 257: 179–85

    Article  PubMed  CAS  Google Scholar 

  38. Kassir AA, Upadhyay AK, Lim TJ, et al. Lack of effect of islet amyloid polypeptide in causing insulin resistance in conscious dogs during euglycemic clamp studies. Diabetes 1991; 40: 998–1004

    Article  PubMed  CAS  Google Scholar 

  39. Butler PC, Chou J, Carter WB, et al. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 1990; 39: 752–6

    Article  PubMed  CAS  Google Scholar 

  40. Steiner DF, Ohagi S, Nagamatsu S, et al. Is islet amyloid polypeptide a significant factor in pathogenesis or pathophysiology of diabetes? Diabetes 1991; 40: 305–9

    Article  PubMed  CAS  Google Scholar 

  41. Tedstone AE, Nezzer T, Hughes SJ, et al. The effect of islet amyloid polypeptide (amylin) and calcitonin gene-related peptide on glucose removal in the anaesthetized rat and on insulin secretion from rat pancreatic islets in vitro. Biosci Rep 1990; 10: 339–45

    Article  PubMed  CAS  Google Scholar 

  42. Bretherton-Watt D, Gilbey SG, Ghatei MA, et al. Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man. Diabetologia 1990; 33: 115–7

    Article  PubMed  CAS  Google Scholar 

  43. Datta HK, Zaidi M, Wimalawansa SJ, et al. In vivo and in vitro effects of amylin and amylin-amide on calcium metabolism in the rat and rabbit. Biochem Biophys Res Commun 1989; 162: 876–81

    Article  PubMed  CAS  Google Scholar 

  44. Bell GI. Molecular defects in diabetes mellitus. Diabetes 1991; 40: 413–22

    Article  PubMed  CAS  Google Scholar 

  45. Westermark P, Johnson KH, O’Brien TD, et al. Islet amyloid polypeptide — a novel controversy in diabetes research. Diabetologia 1992; 35: 297–303

    Article  PubMed  CAS  Google Scholar 

  46. Ammon HP, Reiber C, Verspohl EJ. Indirect evidence for short-loop negative feedback of insulin secretion in the rat. J Endocrinol 1991; 128: 27–34

    Article  PubMed  CAS  Google Scholar 

  47. Ohsawa H, Kanatsuka A, Yamaguchi T, et al. Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Commun 1989; 160: 961–7

    Article  PubMed  CAS  Google Scholar 

  48. Nagamatsu S, Carroll RJ, Grodsky GM, et al. Lack of islet amyloid polypeptide regulation of insulin biosynthesis or secretion in normal rat islets. Diabetes 1990; 39: 871–4

    Article  PubMed  CAS  Google Scholar 

  49. Nagamatsu S, Nishi M, Steiner DF. Effects of islet amyloid polypeptide (IAPP) on insulin biosynthesis or secretion in rat islets and mouse βTC3 cells: biosynthesis of IAPP in mouse βTC3 cells. Diab Res Clin Pract 1992; 15: 49–55

    Article  CAS  Google Scholar 

  50. Broderick CL, Brooke GS, DiMarchi RD, et al. Human and rat amylin have no effects on insulin secretion in isolated rat pancreatic islets. Biochem Biophys Res Commun 1991; 177: 932–8

    Article  PubMed  CAS  Google Scholar 

  51. Fehmann H-C, Weber V, Göke R, et al. Islet amyloid polypeptide (IAPP; amylin) influences the endocrine but not the exocrine rat pancreas. Biochem Biophys Res Commun 1990; 167: 1102–8

    Article  PubMed  CAS  Google Scholar 

  52. Silvestre RA, Peiró E, Dégano P, et al. Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas. Regul Pept 1990; 31: 23–31

    Article  PubMed  CAS  Google Scholar 

  53. Kogire M, Ishizuka J, Thompson JC, et al. Inhibitory action of islet amyloid polypeptide and calcitonin gene-related peptide on release of insulin from the isolated perfused rat pancreas. Pancreas 1991; 6: 459–63

    Article  PubMed  CAS  Google Scholar 

  54. Peiró E, Dégano P, Silvestre RA, et al. Inhibition of insulin release by amylin is not mediated by changes in somatostatin output. Life Sci 1991; 49: 761–5

    Article  PubMed  Google Scholar 

  55. Fürnsinn C, Leuvenink H, Roden M, et al. Inhibition of glucose induced secretion by amylin in rats in vivo [abstract]. Diabetologia 1992; 35Suppl. 1: A29

    Google Scholar 

  56. Wang ZL, Bennet WM, Ghatei MA, et al. Influence of islet amyloid polypeptide and the 8–37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets. Diabetes 1993; 42: 330–5

    Article  PubMed  CAS  Google Scholar 

  57. Dégano P, Silvestre RA, Salas M, et al. Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner: study in the perfused rat pancreas. Regul Pept 1993; 43: 91–6

    Article  PubMed  Google Scholar 

  58. Chuang LM, Wu HP, Jou TS, et al. Inhibitory effect of islet amyloid polypeptide on glucose-induced proinsulin biosynthesis in rat insulinoma cells. Pancreas 1992; 7: 472–6

    Article  PubMed  CAS  Google Scholar 

  59. Young AA, Carlo P, Rink TJ, et al. 8–37hCGRP, an amylin receptor antagonist, enhances the insulin response and perturbs the glucose response to infused arginine in anaesthetized rats. Mol Cell Endocrinol 1992; 84: Rl–5

    Article  Google Scholar 

  60. Silvestre RA, Salas M, Degano P, et al. Reversal of the inhibitory effects of calcitonin gene-related peptide (CGRP) and amylin on insulin secretion by the 8–37 fragment of human CGRP. Biochem Pharmacol 1993; 45: 2343–7

    Article  PubMed  CAS  Google Scholar 

  61. Wagoner PK, Chen C, Worley JF, et al. Amylin modulates beta-cell glucose sensing via effects on stimulus-secretion coupling. Proc Natl Acad Sci USA 1993; 90: 9145–9

    Article  PubMed  CAS  Google Scholar 

  62. Barakat A, Marie J-C, Rosselin G. Direct interaction of islet amyloid polypeptide (IAPP) with calcitonin gene-related peptide (CGRP) receptor present in β cell membrane [abstract]. Diabetologia 1990; 33: A112

    Article  Google Scholar 

  63. Pettersson M, Ahren B, Bottcher G, et al. Calcitonin gene-related peptide: occurrence in pancreatic islets in the mouse and the rat and inhibition of insulin secretion in the mouse. Endocrinology 1986; 119: 865–9

    Article  PubMed  CAS  Google Scholar 

  64. Ahren B, Pettersson M. Calcitonin gene-related peptide (CGRP) and amylin and the endocrine pancreas. Int J Pancreatol 1990; 6: 1–15

    PubMed  CAS  Google Scholar 

  65. Barakat A, Marie J-C, Rosselin G. Le récepteur du peptide apparente au gene de la calcitonine (CGRP) est présent sur les membranes des insulinomes. C R Acad Sci III 1990; 310: 189–94

    PubMed  CAS  Google Scholar 

  66. Lewis CE, Clark A, Ashcroft SJ, et al. Calcitonin gene-related peptide and somatostatin inhibit insulin release from individual rat B cells. Mol Cell Endocrinol 1988; 57: 41–9

    Article  PubMed  CAS  Google Scholar 

  67. Young AA, Wang MW, Cooper GJS. Amylin injection causes elevated plasma lactate and glucose in the rat. FEBS Lett 1991; 291: 101–4

    Article  PubMed  CAS  Google Scholar 

  68. Young AA, Cooper GJS, Carlo P, et al. Response to intravenous injections of amylin and glucagon in fasted, fed, and hypoglycemic rats. Am J Physiol 1993; 264: E943–50

    PubMed  CAS  Google Scholar 

  69. Weischselbaum A, Stangl E. Zur Kenntniss der feineren Veränderungen des Pankreas bei Diabetes mellitus. Wien Klin Wochenschr 1901; 14: 968–72

    Google Scholar 

  70. Opie EL. On the relation of chronic interstitial pancreatitis to the islands of Langerhans and to diabetes mellitus. J Exp Med 1900–01; 5: 397–428

    Article  Google Scholar 

  71. Opie EL. The relation of diabetes mellitus to lesions of the pancreas: hyaline degeneration of the islands of Langerhans. J Exp Med 1900–01; 5: 527–40

    Article  Google Scholar 

  72. Bell ET. Hyalinization of the islets of Langerhans in non-diabetic individuals. Am J Pathol 1959; 35: 801–5

    PubMed  CAS  Google Scholar 

  73. Ahronheim JH. The nature of the hyaline material in the pancreatic islands in diabetes mellitus. Am J Pathol 1943; 19: 873–82

    PubMed  CAS  Google Scholar 

  74. Ehrlich JC, Ratner IM. Amyloidosis of the islets of Langerhans. Am J Pathol 1961; 38: 49–59

    PubMed  CAS  Google Scholar 

  75. Clark A, Cooper GJS, Lewis CE, et al. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet 1987; II: 231–4

    Article  Google Scholar 

  76. Porte Jr D, Kahn SE. Hyperproinsulinemia and amyloid in NIDDM: clues to etiology of islet beta-cell dysfunction? Diabetes 1989; 38: 1333–6

    Article  PubMed  CAS  Google Scholar 

  77. Fox N, Schrementi J, Nishi M, et al. Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM). FEBS Lett 1993; 323: 40–4

    Article  PubMed  CAS  Google Scholar 

  78. Hoppener JW, Oosterwijk C, Verbeek SJ, et al. IAPP/amylin transgenic mice as an in vivo model system for type-2 diabetes mellitus? Biochem Soc Trans 1993; 21: 28S

    PubMed  CAS  Google Scholar 

  79. Lorenzo A, Razzaboni B, Weir GC, et al. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994; 368: 756–60

    Article  PubMed  CAS  Google Scholar 

  80. Himsworth H. Diabetes mellitus: a differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936; I: 127–30

    Article  Google Scholar 

  81. DeFronzo RA. Lilly lecture 1987. The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988; 37: 667–87

    PubMed  CAS  Google Scholar 

  82. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607

    Article  PubMed  CAS  Google Scholar 

  83. Hansen BC, Bodkin NL. Heterogeneity of insulin responses: phases leading to type 2 (non-insulin-dependent) diabetes mellitus in the rhesus monkey. Diabetologia 1986; 29: 713–9

    Article  PubMed  CAS  Google Scholar 

  84. Lillioja S, Mott DM, Howard BV, et al. Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 1988; 318: 1217–25

    Article  PubMed  CAS  Google Scholar 

  85. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989; 321: 337–43

    Article  PubMed  CAS  Google Scholar 

  86. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989; 320: 702–6

    Article  PubMed  CAS  Google Scholar 

  87. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350–7

    Article  PubMed  CAS  Google Scholar 

  88. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39: 167–74

    Article  PubMed  CAS  Google Scholar 

  89. Enoki S, Mitsukawa T, Takemura J, et al. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1992; 15: 97–102

    Article  PubMed  CAS  Google Scholar 

  90. Hanabusa T, Kubo K, Oki C, et al. Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1992; 15: 89–96

    Article  PubMed  CAS  Google Scholar 

  91. Kautzky-Willer A, Thomaseth K, Pacini G, et al. Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 1994; 37: 188–94

    Article  PubMed  CAS  Google Scholar 

  92. Brands MW, Hall JE. Insulin resistance, hyperinsulinemia, and obesity-associated hypertension [editorial]. J Am Soc Nephrol 1992; 3: 1064–77

    PubMed  CAS  Google Scholar 

  93. Hall JE, Brands MW, Mizelle HL, et al. Chronic intrarenal hyperinsulinemia does not cause hypertension. Am J Physiol 1991; 260: F663–9

    PubMed  CAS  Google Scholar 

  94. Briffeuil P, Huynh-Thu T, Kolanowski J. Reappraisal of the role of insulin on sodium handling by the kidney: effect of intrarenal insulin infusion in the dog. Eur J Clin Invest 1992; 22: 523–8

    Article  PubMed  CAS  Google Scholar 

  95. Hall JE, Brands MW, Hildebrandt DA, et al. Obesity-associated hypertension: hyperinsulinemia and renal mechanisms. Hypertension 1992; 19 (1 Suppl.): I45–55

    Article  PubMed  CAS  Google Scholar 

  96. Hall JE, Coleman TG, Mizelle HL, et al. Chronic hyperinsulinemia and blood pressure regulation. Am J Physiol 1990; 258: F722–31

    PubMed  CAS  Google Scholar 

  97. Anderson EA, Balon TW, Hoffman RP, et al. Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension 1992; 19: 621–7

    Article  PubMed  CAS  Google Scholar 

  98. O’Brien T, Young Jr WF, Palumbo PJ, et al. Hypertension and dyslipidemia in patients with insulinoma. Mayo Clin Proc 1993; 68: 141–6

    PubMed  Google Scholar 

  99. Sawicki PT, Baba T, Berger M, et al. Normal blood pressure in patients with insulinoma despite hyperinsulinemia and insulin resistance. J Am Soc Nephrol 1992; 3Suppl. 4: S64–8

    PubMed  CAS  Google Scholar 

  100. Sawicki PT, Heinemann L, Starke A, et al. Hyperinsulinaemia is not linked with blood pressure elevation in patients with insulinoma. Diabetologia 1992; 35: 649–52

    Article  PubMed  CAS  Google Scholar 

  101. Zimmermann S, Phillips RA, Dunaif A, et al. Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metab 1992; 75: 508–13

    Article  PubMed  CAS  Google Scholar 

  102. Nosadini R, Fioretto P, Trevisan R, et al. Insulin-dependent diabetes mellitus and hypertension. Diabetes Care 1991; 14: 210–9

    Article  PubMed  CAS  Google Scholar 

  103. Jarrett RJ. In defence of insulin: a critique of syndrome X. Lancet 1992; 340: 469–71

    Article  PubMed  CAS  Google Scholar 

  104. McAreavey D, Robertson JI. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs 1990; 40: 326–45

    Article  PubMed  CAS  Google Scholar 

  105. Predel HG, Dusing R, Backer A, et al. Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril. Am J Cardiol 1987; 59: 143D–8D

    Article  PubMed  CAS  Google Scholar 

  106. Donnelly R. Angiotensin-Converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes, and heart failure. J Cardiovasc Pharmacol 1992; 20Suppl. 11: S38–44

    Article  PubMed  Google Scholar 

  107. Gotz R, Heidbreder E, Heidland A. Angiotensin-Converting enzyme inhibition in renal and hypertensive disorders. Clin Physiol Biochem 1990; 8Suppl. 1: 25–32

    PubMed  Google Scholar 

  108. Kramer HJ, Predel HG, Meyer-Lehnert H. Angiotensin-Converting enzyme inhibition in patients with essential hypertension. Clin Physiol Biochem 1990; 8Suppl. 1: 16–24

    PubMed  Google Scholar 

  109. Beaumont K, Kenney MA, Young AA, et al. High affinity amylin binding sites in rat brain. Mol Pharmacol 1993; 44: 493–7

    PubMed  CAS  Google Scholar 

  110. Sheriff S, Fischer JE, Balasubramaniam A. Amylin inhibits insulin-stimulated glucose uptake in C2C12 muscle cell line through a cholera-toxin-sensitive mechanism. Biochim Biophys Acta 1992; 1136: 219–22

    Article  PubMed  CAS  Google Scholar 

  111. D’Santos CS, Gatti A, Poyner DR, et al. Stimulation of adenylate cyclase by amylin in CHO-K1 cells. Mol Pharmacol 1992; 41: 894–9

    PubMed  Google Scholar 

  112. Nieuwenhuis MG, van Hulst KL, Hackeng WHL, et al. Islet amyloid polypeptide plasma concentrations in patients with insulinoma [abstract]. Diabetologia 1992; 35Suppl. 1: A119

    Google Scholar 

  113. Stridsberg M, Wilander E, Oberg K, et al. Islet amyloid poly-peptide-producing pancreatic islet cell tumor: a clinical and biochemical characterization. Scand J Gastroenterol 1992; 27: 381–7

    Article  PubMed  CAS  Google Scholar 

  114. Stridsberg M, Berne C, Sandler S, et al. Inhibition of insulin secretion, but normal peripheral insulin sensitivity, in a patient with a malignant endocrine pancreatic tumour producing high amounts of an islet amyloid polypeptide-like molecule. Diabetologia 1993; 36: 843–9

    Article  PubMed  CAS  Google Scholar 

  115. Furnsinn C, Nowotny P, Roden M, et al. Insulin resistance caused by amylin in conscious rats is independent of induced hypocalcaemia and fades during long-term exposure. Acta Endocrinol 1993; 129: 360–5

    PubMed  CAS  Google Scholar 

  116. Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J 1990; 4: 2881–9

    PubMed  CAS  Google Scholar 

  117. Dublineau I, Pradelles P, de Rouffignac C, et al. Differential short-term desensitization to vasopressin, isoproterenol, glucagon, parathyroid hormone and calcitonin in the thick ascending limb of rat kidney. Pflugers Arch 1992; 420: 16–22

    Article  PubMed  CAS  Google Scholar 

  118. Bawab W, Chastre E, Gespach C. Functional and structural characterization of the secretin receptors in rat gastric glands: desensitization and glycoprotein nature. Biosci Rep 1991; 11: 33–42

    Article  PubMed  CAS  Google Scholar 

  119. Dublineau B, Pradelles P, de Rouffignac C, et al. In vitro desensitization of isolated nephron segments to vasopressin. Proc Natl Acad Sci USA 1990; 87: 7583–7

    Article  PubMed  CAS  Google Scholar 

  120. Wilding JPH, Khandan-Nia N, Bennet WM, et al. Lack of acute effect of amylin (islet amyloid polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. Diabetologia 1994; 37: 166–9

    Article  PubMed  CAS  Google Scholar 

  121. Bretherton-Watt D, Gilbey SG, Ghatei MA, et al. Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. J Clin Endocrinol Metab 1992; 74: 1032–5

    Article  PubMed  CAS  Google Scholar 

  122. Roberts AN, Leighton B, Todd JA, et al. Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. Proc Natl Acad Sci USA 1989; 86: 9662–6

    Article  PubMed  CAS  Google Scholar 

  123. Cooper ME, McNally PG, Phillips PA, et al. Amylin stimulates plasma renin concentrations in humans. Hypertension 1995; 26: 460–4

    Article  PubMed  CAS  Google Scholar 

  124. Brain SD, Wimalawansa S, MacIntyre I, et al. The demonstration of vasodilator activity of pancreatic amylin amide in the rabbit. Am J Pathol 1990; 136: 487–90

    PubMed  CAS  Google Scholar 

  125. Young AA, Rink TJ, Wang MW. Dose response characteristics for the hyperglycemic, hyperlactemic, hypotensive and hypocalcemic actions of amylin and calcitonin gene-related peptide-I (CGRP alpha) in the fasted, anaesthetized rat. Life Sci 1993; 52: 1717–26

    Article  PubMed  CAS  Google Scholar 

  126. Gardiner SM, Compton AM, Kemp PA, et al. Antagonistic effect of human alpha-calcitonin gene-related peptide (8–37) on regional hemodynamic actions of rat islet amyloid polypeptide in conscious Long-Evans rats. Diabetes 1991; 40: 948–51

    Article  PubMed  CAS  Google Scholar 

  127. Deems RO, Cardinaux F, Deacon RW, et al. Amylin or CGRP (8–37) fragments reverse amylin-induced inhibition of 14C-glycogen accumulation. Biochem Biophys Res Commun 1992; 181: 116–20

    Article  Google Scholar 

  128. Huang H-JS, Cooper GJS, Young AA, et al. Deficiency of amylin expression in the pancreas of autoimmune BB/Wor diabetic rats [abstract]. J Cell Biochem 1991; Suppl. 15B: 67

    Google Scholar 

  129. Bretherton-Watt D, Ghatei MA, Legon S, et al. Depletion of islet amyloid polypeptide in the spontaneously diabetic (BB) Wistar rat. J Mol Endocrinol 1991; 6: 3–7

    Article  PubMed  CAS  Google Scholar 

  130. Hartter E, Svoboda T, Ludvik B, et al. Basal and stimulated plasma levels of pancreatic amylin indicate its cosecretion with insulin in humans. Diabetologia 1991; 34: 52–4

    Article  PubMed  CAS  Google Scholar 

  131. Sanke T, Hanabusa T, Nakano Y, et al. Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991; 34: 129–32

    Article  PubMed  CAS  Google Scholar 

  132. Young AA, Crocker LB, Wolfe-Lopez D, et al. Daily amylin replacement reverses hepatic glycogen depletion in insulin-treated streptozotocin diabetic rats. FEBS Lett 1991; 287: 203–5

    Article  PubMed  CAS  Google Scholar 

  133. Kolterman OG, Gottlieb A, Moyses C, et al. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC 137, a human amylin analogue. Diabetes Care 1995; 18: 1179–82

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Developmental Biology and Cancer Research Group, School of Biological Sciences and Department of Medicine, University of Auckland School of Medicine, Private Bag 92019, Auckland, New Zealand

    Garth J. S. Cooper & Cynthia A. Tse

Authors
  1. Garth J. S. Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cynthia A. Tse
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cooper, G.J.S., Tse, C.A. Amylin, Amyloid and Age-Related Disease. Drugs & Aging 9, 202–212 (1996). https://doi.org/10.2165/00002512-199609030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199609030-00006

Keywords

Search

Navigation